Phase-II Immunogenicity Study of a DTaP-IPV-Hep B-PRP-T Combined Vaccine Compared With PENTAXIM and ENGERIX B PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants.

Trial Profile

Phase-II Immunogenicity Study of a DTaP-IPV-Hep B-PRP-T Combined Vaccine Compared With PENTAXIM and ENGERIX B PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2013

At a glance

  • Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hepatitis B vaccine recombinant; Hib-DTaP-poliovirus vaccine
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 06 Jun 2011 Results have been published ahead of print in the Pediatric Infectious Disease Journal.
    • 03 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top